74 research outputs found
NGC 6309, a Planetary Nebula that Shifted from Round to Multipolar
We present new narrow-band Ha, [N II], and [O III] high-resolution images of
the quadrupolar planetary nebula (PN) NGC 6309 that show in great detail its
bipolar lobes and reveal new morphological features. New high- and
low-dispersion long-slit spectra have been obtained to help in the
investigation of the new nebular components. The images and spectra unveil two
diffuse blobs, one of them located at 55 arcsec from the central star along the
NE direction (PA= +71) and the other at 78 arcsec in the SW direction (PA=
-151). Therefore, these structures do not share the symmetry axes of the inner
bipolar outflows. Their radial velocities relative to the system are quite low:
+3 and -4 km/s, respectively. Spectroscopic data confirm a high [O III] to Ha
ratio, indicating that the blobs are being excited by the UV flux from the
central star. Our images convincingly show a spherical halo 60 arcsec in
diameter encircling the quadrupolar nebula. The expansion velocity of this
shell is low, 66 km/s. The software SHAPE has been used to construct a
morpho-kinematic model for the ring and the bipolar flows that implies an age
of 4,000 yrs, the expansion of the halo sets a lower limit for its age 46,000
yrs, and the very low expansion of the blobs suggests they are part of a large
structure corresponding to a mass ejection that took place 150,000 yrs ago. In
NGC 6309 we have direct evidence of a change in the geometry of mass-loss, from
spherical in the halo to axially-symmetric in the two pairs of bipolar lobes.Comment: 8 pages, 7 figures, Accepted for publication in MNRA
Modeling Tumor Response after Combined Administration of Different Immune-Stimulatory Agents
Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction
Nimodipine is a 1,4-dihydropyridine derivative that shows a preferential
cerebrovascular activity in experimental animals. Clinical data suggest that
nimodipine has a beneficial effect on the neurologic outcome of patients
suffering an acute ischemic stroke. Our double-blind placebo-controlled
multicenter trial was designed to assess the effects of oral nimodipine on the
mortality rate and neurologic outcome of patients with an acute ischemic stroke.
One hundred sixty-four patients were randomly allocated to receive either
nimodipine tablets (30 mg q.i.d.) or identical placebo tablets for 28 days.
Treatment was always started less than or equal to 48 hours after the acute
event. The Mathew Scale, slightly modified by Gelmers et al, was used for
neurologic assessment. Mortality rate and neurologic outcome after 28 days were
used as evaluation criteria. We considered 123 patients to be valid for the
analysis of efficacy. Mortality rates did not differ significantly between
groups. Neurologic outcome after 28 days of therapy did not differ between
groups. However, when only those patients most likely to benefit from any
intervention (Mathew Scale sum score of less than or equal to 65 at baseline)
were analyzed separately in post hoc-defined subgroups, the nimodipine-treated
subgroups showed a significantly better neurologic outcome. This result suggests
that some patients with acute ischemic stroke will benefit from treatment with
nimodipine tablets
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
Background: To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s
disease, supportive biomarker information is necessary. This study was aimed to investigate the association of
plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by
amyloid-PET. Both plasma Aβ42/40 ratio alone or combined with an FDG-PET-based biomarker of
neurodegeneration were assessed as potential AD biomarkers.
Methods: We included 39 cognitively normal subjects and 20 patients with mild cognitive impairment from the
AB255 Study who had undergone PiB-PET scans. Total Aβ40 and Aβ42 levels in plasma (TP42/40) were quantified
using ABtest kits. Subjects were dichotomized as Aβ-PET positive or negative, and the ability of TP42/40 to detect
Aβ-PET positivity was assessed by logistic regression and receiver operating characteristic analyses. Combination of
plasma Aβ biomarkers and FDG-PET was further assessed as an improvement for brain amyloidosis detection and
diagnosis classification.
Results: Eighteen (30.5%) subjects were Aβ-PET positive. TP42/40 ratio alone identified Aβ-PET status with an area
under the curve (AUC) of 0.881 (95% confidence interval [CI] = 0.779–0.982). Discriminating performance of TP42/40
to detect Aβ-PET-positive subjects yielded sensitivity and specificity values at Youden’s cutoff of 77.8% and 87.5%,
respectively, with a positive predictive value of 0.732 and negative predictive value of 0.900. All these parameters
improved after adjusting the model for significant covariates. Applying TP42/40 as the first screening tool in a
sequential diagnostic work-up would reduce the number of Aβ-PET scans by 64%. Combination of both FDG-PET
scores and plasma Aβ biomarkers was found to be the most accurate Aβ-PET predictor, with an AUC of 0.965 (95%
CI = 0.913–0.100).
Conclusions: Plasma TP42/40 ratio showed a relevant and significant potential as a screening tool to identify brain
Aβ positivity in preclinical and prodromal stages of Alzheimer’s disease
Use of tocilizumab in kidney transplant recipients with COVID-1
Acute respiratory distress syndrome associated with coronavirus infection is related to a cytokine storm with large interleukin-6 (IL-6) release. The IL-6-receptor blocker tocilizumab may control the aberrant host immune response in patients with coronavirus disease 2019 (COVID-19) . In this pandemic, kidney transplant (KT) recipients are a high-risk population for severe infection and showed poor outcomes. We present a multicenter cohort study of 80 KT patients with severe COVID-19 treated with tocilizumab during hospital admission. High mortality rate was identified (32.5%), related with older age (hazard ratio [HR] 3.12 for those older than 60 years, P = .039). IL-6 and other inflammatory markers, including lactic acid dehydrogenase, ferritin, and D-dimer increased early after tocilizumab administration and their values were higher in nonsurvivors. Instead, C-reactive protein (CRP) levels decreased after tocilizumab, and this decrease positively correlated with survival (mean 12.3 mg/L in survivors vs. 33 mg/L in nonsurvivors). Each mg/L of CRP soon after tocilizumab increased the risk of death by 1% (HR 1.01 [confidence interval 1.004-1.024], P = .003). Although patients who died presented with worse respiratory situation at admission, this was not significantly different at tocilizumab administration and did not have an impact on outcome in the multivariate analysis. Tocilizumab may be effective in controlling cytokine storm in COVID-19 but randomized trials are needed
Código de conduta. Prevenção da introdução e dispersão de flora e fauna exótica invasora: agentes ambientais
De forma intencional ou involuntária, o ser humano transporta espécies entre locais desde tempos imemoriais. No entanto, nos últimos 50 anos, o ritmo de introdução de espécies exóticas no meio natural acelerou de forma alarmante, tornando-se numa das principais causas de perda de biodiversidade. A globalização, juntamente com as alterações climáticas, a destruição de habitats, o aumento do trânsito de pessoas e o comércio, são hoje os principais responsáveis pela perda de biodiversidade a nível global, acarretando também graves prejuízos para a economia e a saúde humana
Human toxocariasis: contribution by Brazilian researchers
In the present paper the main aspects of the natural history of human infection by Toxocara larvae that occasionally result in the occurrence of visceral and/or ocular larva migrans syndrome were reviewed. The contribution by Brazilian researchers was emphasized, especially the staff of the Tropical Medicine Institute of São Paulo (IMT)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. For example, a key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process versus those that measure fl ux through the autophagy pathway (i.e., the complete process including the amount and rate of cargo sequestered and degraded). In particular, a block in macroautophagy that results in autophagosome accumulation must be differentiated from stimuli that increase autophagic activity, defi ned as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (inmost higher eukaryotes and some protists such as Dictyostelium ) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the fi eld understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. It is worth emphasizing here that lysosomal digestion is a stage of autophagy and evaluating its competence is a crucial part of the evaluation of autophagic flux, or complete autophagy. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. Along these lines, because of the potential for pleiotropic effects due to blocking autophagy through genetic manipulation it is imperative to delete or knock down more than one autophagy-related gene. In addition, some individual Atg proteins, or groups of proteins, are involved in other cellular pathways so not all Atg proteins can be used as a specific marker for an autophagic process. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular autophagy assays, we hope to encourage technical innovation in the field
- …